Three predictions for biotech in 2023

After a difficult year for investment, look for the biotech industry to engage in creative dealmaking in the market, leading to faster innovation in the lab,  Protagonist Therapeutics CEO Dinesh Patel writes in Bio.News.

Mr Patel noted that a rocky market led to mass layoffs and closures while initial public offerings (IPOs) slowed to a trickle, and dealmaking was slower in comparison to historical norms. He has three predictions for 2023.

Expect ingenuity in dealmaking